Short answer
BridgeBio Oncology Therapeutics Inc (BBOT) filed an 8-K current report with the SEC on August 11, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Press release announces BridgeBio Oncology Therapeutics’ financial results for quarter ended June 30, 2026.
BridgeBio Oncology Therapeutics Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release announces BridgeBio Oncology Therapeutics’ financial results for quarter ended June 30, 2026
- Exhibit 99.1 contains the detailed results investors should review for performance and financial condition metrics
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 net loss $56.5M, nearly doubling from $28.4M as development spending accelerated
- R&D expense $49.2M versus $27.4M, driven by clinical-trial and manufacturing investment across three programs
- Cash, equivalents and marketable securities $344.1M, with runway expected into 2028 despite $81.3M decline from December
- Combination dosing expanded across BBO-8520, BBO-11818 and BBO-10203, increasing potential efficacy while raising execution risk
- Multiple clinical milestones expected in second half of 2026, creating near-term catalysts for investors
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other BridgeBio Oncology Therapeutics Inc 8-K filings
Get the next BBOT 8-K as it lands
Follow BBOT for push alerts, or ask the research agent what this filing means.